The significant overlap of RNA binding targets between CSDE1 and FMRP suggests that behavioral and potential therapeutic interventions (40) for FXS are also likely to benefit patients with CSDE1-related syndrome. The gene discussed is CSDE1; the disease is fragile X syndrome.